Abstract:Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant erlotinib therapy improves 2-year disease-free survival compared with chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive stage IIIA NSCLC. Methods In this randomised, open-label, phase 2 trial, eligible patients aged 18-75 years who had undergone complete (RO) resection of histologically or pathologically confirmed stage IIIA EGFR mutation-positive NSCLC and had not received any previous anticancer therapies were enrolled. Patients were randomly assigned (1:1) to receive either adjuvant erlotinib (150 mg once daily administered orally) or vinorelbine and cisplatin chemotherapy (four cycles of vinorelbine [25 mg/m(2) intravenously on days 1 and 8 of each 21-day cycle] plus cisplatin [75 mg/m(2) intravenously on day 1 of each 21-day cycle]). Randomisation was done by Simon's minimisation with a random element and was stratified by EGFR activating mutation type (exon 19 vs 21), histology (adenocarcinoma vs non-adenocarcinoma), and smoking status (smoker vs non-smoker). The primary endpoint in the unblinded intention-to-treat analysis was 2-year disease-free survival. This ongoing study is registered with ClinicalTrials.gov , number NCT01683175. Findings Between Sept 8, 2012, and May 21, 2015, 102 patients from 16 centres across China were enrolled and randomly assigned to receive erlotinib (n=51) or chemotherapy (n=51). Median follow-up was 33.0 months (IQR 17-8-43-1). 2-year disease-free survival was 81.4% (95% CI 69.6-93.1) in the erlotinib group and 44.6% (26 -9-62- 4) in the chemotherapy group (relative risk 1.823 [95% CI 1.194-2.784; p=0.0054). The difference in 2-year disease-free survival between the groups was 36.7% (95% CI 15 - 5-58- 0; p=0.0007). Adverse events of any grade occurred in 29 (58%) of 50 patients in the erlotinib group and 28 (65%) of 43 patients in the chemotherapy group. Grade 3 or worse adverse events occurred in six (12%) of 50 patients in the erlotinib group versus 11 (26%) of 43 in the chemotherapy group; the most common of these in the erlotinib group was rash (in two 14%1 of 50 patients) and in the chemotherapy group were decreased neutrophil count (in seven [16%] of 43 patients) and myelosuppression (in four [9%]). No treatment-related deaths were reported. Interpretation Adjuvant erlotinib improved 2-year disease-free survival in patients with EGFR mutation-positive stage IIIA NSCLC compared with chemotherapy, with a better tolerability profile. This study suggests that tyrosine kinase inhibitors could have a potentially important role as adjuvant therapy in EGFR mutation-positive stage IIIA NSCLC. However, this trial was a phase 2 study. Mature overall survival data are also needed. Ongoing studies will hopefully confirm the role of adjuvant EGFR tyrosine kinase inhibitor therapy in patients with NSCLC. Copyright (C) 2018 Elsevier Ltd. All rights reserved.

Randomized Trial of High-dose Epirubicin for the Treatment of Non-small Cell Lung Cancer

Comparable Efficacy and Less Toxicity of Pegylated Liposomal Doxorubicin Versus Epirubicin for Neoadjuvant Chemotherapy of Breast Cancer: a Case-Control Study

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Clinical Observation of Epirubicin-contained Chemotherapeutic Regimens in Non-small Cell Lung Cancer

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

Randomized Phase Iii Study Of Recombinant Human Apo-2 Ligand (Apo-2 Ligand) Plus Vinorelbine/Cisplatin (Np) Verus Placebo Plus Np In Patients With Stage Iiib/Iv Non-Small Cell Lung Cancer (Nsclc): A Single Center Report.

The Efficacy and Relationship Between Peak Concentration and Toxicity Profile of Fixed-Dose-Rate Gemcitabine Plus Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer

Etoposide-cisplatin alternating with vinorelbine-cisplatin versus etoposide-cisplatin alone in patients with extensive disease combined with small cell lung cancer.

Erlotinib Versus Etoposide/Cisplatin with Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

Erlotinib Versus Vinorelbine Plus Cisplatin As Adjuvant Therapy in Chinese Patients with Stage IIIA EGFR Mutation-Positive Non-Small-cell Lung Cancer (EVAN): a Randomised, Open-Label, Phase 2 Trial.

Randomized Phase III Trial of Amrubicin/cisplatin Versus Etoposide/cisplatin As First-Line Treatment for Extensive Small-Cell Lung Cancer.

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

Clinical and Pharmacokinetics Study of Oral Low-dose Etoposide in Non-smiallcell Lung Cancer

Comparative Study of Iobaplatin and Cisplatin Combined with Etoposide for Advanced Small Cell Lung Cancer

A Randomized Comparative Trial of NVB Alone Versus NVB Plus DDP for Treatment of Elderly Patients with Non-Small Cell Lung Cancer

Comparison of Short-term Efficacy between the NP and GP Regimens in the Treatment of Advanced Non-small-cell Lung Canaer

Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation with Concurrent Twice-daily Radiotherapy for Patients with Limited-stage Small Cell Lung Cancer

A Double-Blind, Randomized Phase II Study of Dicycloplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel As First-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancers.

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

[Prospective Non-Randomized Study of Chemotherapy Combined with Radiotherapy Versus Chemotherapy Alone in Patients with Metastatic or Relapsed Esophageal Squamous Cell Carcinoma].

Clinical observation of IEP followed EP chemotherapy in treatment of extensive-stage small cell lung cancer